

September 20, 2018



# Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease

NEW YORK, Sept. 20, 2018 /PRNewswire/ --**Actinium Pharmaceuticals, Inc.** (NYSE AMERICAN: ATNM) today announced that the Company will participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma and Rare Disease, to be held September 26-27, 2018 in New York City. Management will be hosting one-on-one meetings at the conference as follows:

Date: Thursday, September 27, 2018  
Time: 8:00 am to 5:00 pm (ET)  
Location: The Langham Hotel, New York City



To schedule a meeting with Actinium, please contact Steve O'Loughlin, Principal Financial Officer via email [soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com) or through the Oppenheimer conference website <https://www.opco.com/conferences/nypharma18/index.aspx>.

## About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.

Iomab-B, Actinium's lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium's pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in

Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.

Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.

More information is available at [www.actiniumpharma.com](http://www.actiniumpharma.com) and our Twitter feed @ActiniumPharma, [www.twitter.com/actiniumpharma](http://www.twitter.com/actiniumpharma).

### **Forward-Looking Statements for Actinium Pharmaceuticals, Inc.**

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

### **Contact:**

#### **Actinium Pharmaceuticals, Inc.**

Steve O'Loughlin  
Principal Financial Officer  
[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

#### **Investor Relations**

Rx Communications Group  
Paula Schwartz  
917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)

Susan A. Noonan  
212-966-3650  
[investorrelations@actiniumpharma.com](mailto:investorrelations@actiniumpharma.com)

🔗 View original content to download multimedia <http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-participate-in-the-oppenheimer--co-fall-summit-focused-on-specialty-pharma-and-rare-disease-300715908.html>

SOURCE Actinium Pharmaceuticals, Inc.